On Nov. 1, 2022, the Medicines Control Authority of Zimbabwe announced that it had approved the use of long-acting injectable cabotegravir as pre-exposure prophylaxis for HIV prevention.

WHO recommended that CAB-LA may be offered to people at substantial risk of HIV infection as part of comprehensive HIV prevention. Theﾠ U.S. Food and Drug Administration approved its use for HIV prevention in December 2021, and Australia’s Therapeutic Goods Administration approved it in August 2022.